Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2007

01-01-2007

Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base

Authors: Christopher M. Pezzi, MD, Lina Patel-Parekh, MHA, CHE, Karin Cole, MD, Jan Franko, MD, PhD, V. Suzanne Klimberg, MD, Kirby Bland, MD

Published in: Annals of Surgical Oncology | Issue 1/2007

Login to get access

Abstract

Background

Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized as a distinct pathologic diagnosis in 2000. With few published reports, we hypothesized that MBC may have markedly different characteristics at presentation than typical infiltrating ductal carcinoma (IDC) and may be managed differently.

Methods

Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson χ2 test.

Results

A total of 892 patients with MBC and 255,164 patients with IDC were identified. The group with MBC was older (mean age, 61.1 vs. 59.7 years; P = .001), had a significantly increased proportion of African American (14.1%, 126 of 892, vs. 10.2%, 25,900 of 255,164; odds ratio [OR], 1.455, P = .001) and Hispanic patients (5.5%, 49 of 892 vs. 3.9%, 9,947 of 255,164; OR, 1.817, P = .001), had fewer T1 tumors (29.5% vs. 65.2%), more N0 tumors (78.1% vs. 65.7%, OR, .5, P = .001), more poorly or undifferentiated tumors (67.8% vs. 38.8%), and fewer estrogen receptor–positive tumors (11.3% vs. 74.1%, OR, 22.4, P = .001) than the IDC group. Patients with MBC were treated with breast-conserving surgery less frequently than patients with IDC (38.5% vs. 55.8%, OR, 2.0, P = .001) because of the larger tumor size. Chemotherapy was used more often for patients with MBC (53.4% vs. 42.1%, OR, 1.6, P = .001) because of more advanced AJCC stage.

Conclusions

MBC is a rare tumor with different characteristics than IDC: it presents with larger tumor size, less nodal involvement, higher tumor grade, and hormone receptor negativity. Patients with MBC are treated more aggressively than IDC (more often with mastectomy and chemotherapy) because of a higher stage at presentation, but are being treated by the same principles as IDC. Follow-up will determine the long-term results of the current treatment.
Appendix
Available only for authorised users
Literature
1.
Fritz A, Percy C, Jack A, Solin LH, eds. (2000) International Classification of Diseases of Oncology. 3rd ed. Geneva: World Health Organization.
2.
Pitts WC, Rojas VA, Gaffey MJ, et al. Carcinomas with metaplasia and sarcomas of the breast. Am J Clin Pathol 1991; 95:623–32PubMed
3.
Kurian KM, Al-Nafussi Al. Sarcomatoid/metaplastic carcinoma of the breast: a clinicopathological study of 12 cases. Histopathology 2002; 40:58–64PubMedCrossRef
4.
Johnson TL, Kini SR. Metaplastic breast carcinoma: a cytohistologic and clinical study of 10 cases. Diagn Cytopathol 1996; 14:226–32PubMedCrossRef
5.
Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer 1999; 85:2170–82PubMedCrossRef
6.
Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol 1999 ; 71:220–5PubMedCrossRef
7.
Bellino R, Arisio R, D’Addato F, et al. Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res 2003; 23:669–73PubMed
8.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989; 20:628–35PubMedCrossRef
9.
Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989; 20:732–40PubMedCrossRef
10.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989; 64:1490–9PubMedCrossRef
11.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990; 65:272–6PubMedCrossRef
12.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990; 21:1142–50PubMedCrossRef
13.
Park JM, Han BK, Moon WK, et al. Metaplastic carcinoma of the breast: mammographic and sonographic findings. J Clin Ultrasound 2000; 28:179–86PubMedCrossRef
14.
Gunhan-Bilgen I, Memis A, Ustun EE, Zekioglu O, Ozdemir N. Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. Am J Roentgenol 2002; 178:1421–5
15.
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999; 10:413–9PubMedCrossRef
16.
Oberman HA. Metaplastic carcinoma of the breast: a clinicopathologic study of 29 patients. Am J Surg Pathol 1987; 11:918–29PubMedCrossRef
17.
Saxena S, Bansal A, Mohil RS, Bhatnagar D. Metaplastic carcinoma of the breast—a rare breast tumour. Indian J Pathol Microbiol 2004; 47:217–20PubMed
18.
Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma: rare form of mammary cancer. NY State J Med 1973; 73:1078–82
19.
Grechi G, Pagnini P. Study of mammary gland neoplasms with an osteocartilaginous component. I. Cartilaginous metaplastic epiphenomena in the course of connective tissue malignancy. Arch De Vecchi Anat Patol 1965; 46:277–303PubMed
Metadata
Title
Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base
Authors
Christopher M. Pezzi, MD
Lina Patel-Parekh, MHA, CHE
Karin Cole, MD
Jan Franko, MD, PhD
V. Suzanne Klimberg, MD
Kirby Bland, MD
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9124-7

Other articles of this Issue 1/2007

Annals of Surgical Oncology 1/2007 Go to the issue

OriginalPaper

Local Involvement of the Urinary Bladder in Primary Colorectal Cancer: Outcome with En-Bloc Resection

OriginalPaper

Major Liver Resections Synchronous with Colorectal Surgery

OriginalPaper

Complications after Extended (D2) and Superextended (D3) Lymphadenectomy for Gastric Cancer: Analysis of Potential Risk Factors

OriginalPaper

Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer

OriginalPaper

Impact of Regional Lymph Node Evaluation in Staging Patients With Periampullary Tumors

OriginalPaper

Abdominal Sacral Resection for Posterior Pelvic Recurrence of Rectal Carcinoma: Analyses of Prognostic Factors and Recurrence Patterns